Back to Search Start Over

Deletion of 18q is a strong and independent prognostic feature in prostate cancer

Authors :
Maximilian Graunke
Hartwig Huland
Christina Möller-Koop
Frank Jacobsen
Claudia Hube-Magg
Stefan Steurer
Sarah Minner
Till S. Clauditz
Corinna Wittmer
Ronald Simon
Thorsten Schlomm
Andrea Hinsch
Martina Kluth
Franziska Büscheck
Patrick Lebok
Raisa S. Pompe
Guido Sauter
Uwe Michl
Waldemar Wilczak
Markus Graefen
Source :
Oncotarget
Publication Year :
2016

Abstract

// Martina Kluth 1, * , Maximilian Graunke 1, * , Christina Moller-Koop 1 , Claudia Hube-Magg 1 , Sarah Minner 1 , Uwe Michl 2 , Markus Graefen 2 , Hartwig Huland 2 , Raisa Pompe 2 , Frank Jacobsen 1 , Andrea Hinsch 1 , Corinna Wittmer 1 , Patrick Lebok 1 , Stefan Steurer 1 , Franziska Buscheck 1 , Till Clauditz 1 , Waldemar Wilczak 1 , Guido Sauter 1 , Thorsten Schlomm 2, 3 , Ronald Simon 1 1 Institute of Pathology, Prostate Cancer Center at University Medical Center Hamburg-Eppendorf, Germany 2 Martini-Clinic, Prostate Cancer Center at University Medical Center Hamburg-Eppendorf, Germany 3 Department of Urology, Section for prostate cancer research, University Medical Center Hamburg-Eppendorf, Germany * These authors contributed equally to this work Correspondence to: Ronald Simon, email: r.simon@uke.de Keywords: 18q deletion, prostate cancer, prognosis, tissue microarray Received: September 27, 2016 Accepted: November 02, 2016 Published: November 16, 2016 ABSTRACT Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers ( P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors ( P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors ( P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests.

Details

ISSN :
19492553
Volume :
7
Issue :
52
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....df347f390c973636f22ed49e581ac9fa